Abstract: SA-PO752
National Trends and Outcomes of Hospitalizations among Patients with Renal Vasculitides
Session Information
- ANCA-Associated Vasculitis, Anti-GBM Disease, and Other RPGN
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Nebuwa, Chikodili N., Nuvance Health, Vassar Brothers Medical Center, Poughkeepsie, New York, United States
- Ukoha, Nnenna Ann, East Tennessee State University, Johnson City, Tennessee, United States
- Oboli, Victor N., Lincoln Medical Center, Bronx, New York, United States
- Omosumwen, Ede, Richmond Gabriel University, Arnos Vale, Saint Vincent and the Grenadines
- Asobara, Evaristus, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra, Nigeria
Background
Renal vasculitides are a rare and often debilitating diseases characterized by inflammation of blood vessels within the kidneys with risk for severe renal complications. This study aims to characterize recent trends in hospitalization and clinical outcomes for renal vasculitides.
Methods
We used data from NIS between 2017 and 2020 for vasculitides among patients hospitalized for diseases of the kidney and urinary tract (Major Diagnostic Category 11). Diagnoses and comorbidities were identified using CCSR and ICD 10th edition codes. We used pearson chi-square tests to compare baseline characteristics. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay (LOS) and need for dialysis. Cochran-Armitage tests were used for trend analysis with statistical significance set at P<0.05.
Results
We analyzed a total of 9,090 hospitalizations for renal vasculitides. The frequencies were: Granulomatosis with polyangiitis (GPA) (28.5%), anti-glomerular basement membrane disease (anti-GBM) (24.8%), hypocomplementemic urticarial vasculitis syndrome (24.8%), cryoglobulinemic vasculitis (12.5%), Bechet’s disease (16.7%), eosinophilic granulomatosis with polyangiitis (8.5%), and polyarteritis nodosa (PAN) (8.9%).The cohort was predominantly female (51.7%), mean age of 55.2 ± 0.4 years. The annual hospitalizations reduced from 2,730 in 2017 to 1,740 in 2020 (P<0.001). A total of 255 mortalities (2.8%) were recorded in the study period, mostly among females (130), White Americans (160). Mortalities reduced from 85 in 2017 to 35 in 2020 (P<0.001). The greatest mortalities were recorded in the GPA (112; 4.3%) and PAN cohorts (34; 4.25%). Mean LOS was 9 days overall. Patients with Bechet’s disease spent 5.5 days compared to GPA (11.2 ± 0.5 days). No significant change in LOS was recorded from 2017 to 2020 (8.9 vs 9.4 days; p=0.749). About 795 (8.7%) required dialysis. Most patients dialyzed were men (410) and patients with anti-GBM disease (400) or GPA (274). The mean cost of hospitalization over the study period was $110,895.4 =/-4,003, with increase in cost from $95,891 in 2017 to $125,695 in 2020 (p<0.0001)
Conclusion
The study highlights the hospitalization pattern of renal vasculitides. Hospitalization for renal vasculitides, in-hospital mortality and dialysis requirement decreased significantly over the study period.